Interrater reliability of the clinical dementia rating in a multicenter trial

Kenneth Rockwood, David Strang, Chris MacKnight, Robert Downer, John C. Morris

Research output: Contribution to journalArticlepeer-review

63 Scopus citations


OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial. DESIGN: Observational study. SETTING: Training session for a multicenter trial of milameline, a direct muscarinic agonist, in the treatment of Alzheimer's disease. PARTICIPANTS: Twenty-four raters (physicians and nurses) familiar with drug trials and expert in the care of patients with Alzheimer's disease. METHODS: Independent scoring of the CDR using four videotaped CDR interviews. OUTCOME MEASURE: Interrater reliability, as tested by the Kappa statistic RESULTS: The overall interrater reliability was 0.62. Within the CDR domains, the global kappas ranged from 0.33 ± 0.06 to 0.88 ± 0.06. CONCLUSIONS: The data support moderate to high overall interrater reliability but show important difficulties in the reliable assessment of early dementia.

Original languageEnglish
Pages (from-to)558-559
Number of pages2
JournalJournal of the American Geriatrics Society
Issue number5
StatePublished - May 2000


  • Alzheimer's disease
  • Clinical dementia rating
  • Reliability


Dive into the research topics of 'Interrater reliability of the clinical dementia rating in a multicenter trial'. Together they form a unique fingerprint.

Cite this